PMID- 29048237
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220408
IS  - 1557-9077 (Electronic)
IS  - 1050-7256 (Linking)
VI  - 28
IP  - 1
DP  - 2018 Jan
TI  - Lenvatinib for the Treatment of Radioiodine-Refractory Thyroid Cancer in 
      Real-Life Practice.
PG  - 72-78
LID - 10.1089/thy.2017.0205 [doi]
AB  - Background: In the Study of (E7080) Lenvatinib in Differentiated Cancer of the 
      Thyroid (SELECT) phase 3 trial on advanced radioactive iodine-refractory 
      differentiated thyroid cancer (rDTC), lenvatinib improved median progression-free 
      survival over placebo by almost 15 months and induces an objective response rate 
      of 64.8%, but adverse events occurred in almost all patients. The present study 
      evaluates the efficacy and toxicity of lenvatinib treatment in real-life 
      practice. Methods: Clinical charts of 88 consecutive patients treated with 
      lenvatinib from July 2015 to June 2016 in 27 French centers were retrospectively 
      reviewed. Patients treated for other thyroid cancer types (n = 11) or previously 
      treated with lenvatinib within a trial (n = 2) were excluded and the remaining 75 
      rDTC patients formed the basis of this report. Results: 75 rDTC patients were 
      analyzed (33 females, median age 65 years [range, 35-88 years]), 12 had an 
      Eastern Cooperative Oncology Group performance status >/=2; 24 cases received 
      lenvatinib as first line systemic treatment; 47 (63%) patients had documented 
      progressive disease prior to treatment initiation. Distant metastases were 
      located in lungs, bones, and lymph nodes (89%, 60%, and 69%, respectively). The 
      initial treatment dose was 24 mg in 54 patients and was lower in the other 21 
      patients. The median follow-up was 7 months, with a median duration of treatment 
      of 6 months [0.3-15]. Median progression-free survival was 10 months. Among the 
      65 patients with evaluation of tumor response during treatment, best tumor 
      response was a partial response in 23 patients (31%) and stable disease in 38 
      (51%). Eleven patients (14.7%) discontinued lenvatinib because of disease 
      progression. Forty-four (59%) and 23 (31%) patients had dose reductions or an 
      interruption of lenvatinib for adverse events (AEs). The most frequent AEs 
      related to treatment were fatigue, hypertension, weight loss, diarrhea, and 
      anorexia. Eleven deaths occurred during the study (one considered to be drug 
      related). Pneumothorax occurred in 2 patients with lung metastases. Conclusions: 
      Real-life patients with rDTC can benefit from lenvatinib treatment. AEs are 
      frequent and should be closely monitored.
FAU - Berdelou, Amandine
AU  - Berdelou A
AD  - Department of Nuclear Medicine and Endocrine Oncology, Gustave Roussy and 
      Universite Paris-Saclay, Villejuif, France.
AD  - Department of Nuclear Medicine and Endocrine Oncology, Institut Curie, 
      Saint-Cloud, France.
FAU - Borget, Isabelle
AU  - Borget I
AD  - Department of Biostatistics and Epidemiology, Gustave Roussy, CESP, and 
      Universite Paris-Saclay, Villejuif, France.
FAU - Godbert, Yann
AU  - Godbert Y
AD  - Department of Nuclear Medicine, Institut Bergonie, Bordeaux, France.
FAU - Nguyen, Thierry
AU  - Nguyen T
AD  - Department of Medical Oncology, Centre Hospitalier Universitaire Minjoz, 
      Besancon, France.
FAU - Garcia, Marie-Eve
AU  - Garcia ME
AD  - Department of Multidisciplinary Oncology and Therapeutic Innovations, Assistance 
      Publique-Hopitaux de Marseille, Marseille, France.
FAU - Chougnet, Cecile N
AU  - Chougnet CN
AD  - Department of Nuclear Medicine and Endocrine Oncology, Hopital Saint Louis, 
      Assistance Publique-Hopitaux de Paris, France.
FAU - Ferru, Aurelie
AU  - Ferru A
AD  - Department of Medical Oncology, Centre Hospitalier Universitaire de Poitiers, 
      Poitiers, France.
FAU - Buffet, Camille
AU  - Buffet C
AD  - Department of Endocrinology, Hopital de la Pitie Salpetriere, Assistance 
      Publique-Hopitaux de Paris and Universite Pierre et Marie Curie, France.
FAU - Chabre, Olivier
AU  - Chabre O
AD  - Department of Endocrinology, Centre Hospitalier Universitaire de Grenoble, 
      Grenoble, France.
FAU - Huillard, Olivier
AU  - Huillard O
AD  - Department of Medical Oncology, Hopital Cochin, Assistance Publique-Hopitaux de 
      Paris, Universite Paris Descartes, Paris, France.
FAU - Leboulleux, Sophie
AU  - Leboulleux S
AD  - Department of Nuclear Medicine and Endocrine Oncology, Gustave Roussy and 
      Universite Paris-Saclay, Villejuif, France.
FAU - Schlumberger, Martin
AU  - Schlumberger M
AD  - Department of Nuclear Medicine and Endocrine Oncology, Gustave Roussy and 
      Universite Paris-Saclay, Villejuif, France.
LA  - eng
PT  - Journal Article
DEP - 20171127
PL  - United States
TA  - Thyroid
JT  - Thyroid : official journal of the American Thyroid Association
JID - 9104317
SB  - IM
CIN - Nat Rev Endocrinol. 2017 Nov 9;13(12):688. PMID: 29118352
OTO - NOTNLM
OT  - differentiated thyroid cancer
OT  - efficacy
OT  - lenvatinib
OT  - toxicity
OT  - tyrosine kinase inhibitor
EDAT- 2017/10/20 06:00
MHDA- 2017/10/20 06:01
CRDT- 2017/10/20 06:00
PHST- 2017/10/20 06:00 [pubmed]
PHST- 2017/10/20 06:01 [medline]
PHST- 2017/10/20 06:00 [entrez]
AID - 10.1089/thy.2017.0205 [doi]
PST - ppublish
SO  - Thyroid. 2018 Jan;28(1):72-78. doi: 10.1089/thy.2017.0205. Epub 2017 Nov 27.